Hormonal
Chronic dynamic aerobic endurance training significantly reduces resting and ambulatory blood pressure in both normotensive and hypertensive adults, with the magnitude of reduction being greater in hypertensive individuals.
Engage in moderate-intensity aerobic exercise (like brisk walking, jogging, or cycling) for about 40 minutes, 3 times a week. You do not need to exercise at high intensities to see blood pressure benefits. This routine has been shown to lower blood pressure effectively, with greater benefits for those who already have hypertension. Consistency over several weeks is key.
training induced significant net reductions of resting and daytime ambulatory blood pressure of, respectively, 3.0/2.4 mm Hg (P<0.001) and 3.3/3.5 mm Hg (P<0.01). The reduction of resting blood pressure was more pronounced in the 30 hypertensive study groups (-6.9/-4.9) than in the others (-1.9/-1.6; P<0.001 for all).
Why this rating
This is a meta-analysis of 72 randomized controlled trials involving 3936 participants, providing high statistical power and robust evidence.
Source
Effects of Endurance Training on Blood Pressure, Blood Pressure–Regulating Mechanisms, and Cardiovascular Risk Factors
Véronique Cornelissen et al. · Hypertension · 2005
DOI 10.1161/01.hyp.0000184225.05629.51
More from this paper
- Aerobic endurance training reduces blood pressure by decreasing systemic vascular resistance, mediated by reductions in sympathetic nervous system activity (plasma norepinephrine) and renin-angiotensin system activity (plasma renin activity).Good
- Aerobic endurance training favorably affects concomitant cardiovascular risk factors, including reducing body weight, body fat, waist circumference, and insulin resistance, while increasing HDL cholesterol.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →